Process for the preparation of S-N,N′-bis...

Details Process for the preparation of S-N,N′-bis... Process for the preparation of S-N,N′-bis...

2001-03-28

2002-02-26

Barts, Samuel (Department: 1621)

Organic compounds -- part of the class 532-570 series

Organic compounds

Amino nitrogen containing

C564S153000, C564S155000, C564S158000

Reexamination Certificate

active

06350908

ABSTRACT:

This is the National phase application of PCT/EP9905686, filed Aug. 6, 1999.
The present invention relates to a process for the preparation of S-N,N′-bis[2-hydroxy-1-(hydroxymethyl)-ethyl]-5-[(2-hydroxy-1-oxopropyl)-amino]-2,4,6-triiodo-1,3-benzenedicarboxamide of formula (I), more commonly known as Iopamidol, which is one of the world top compounds in the field of iodinated contrast agents, which process comprises a novel step for the synthesis of the intermediate S-N,N′-bis[2-hydroxy-1-(hydroxymethyl)ethyl]-5-[(2-(acetyloxy)-1-oxopropyl)-amino]-2,4,6-triiodo-1,3-benzenedicarboxamide of formula (II).
The synthesis of Iopamidol was described first in GB 1.472.050 and it involves the steps represented in the following Scheme:
and precisely the reaction of S-(−)-5-[[2-(acetyloxy)-1-oxopropyl]amino]-2,4,6-triiodo-1,3-benzenedicarboxylic acid dichloride of formula (III) dissolved in dimethylacetamide (DMAC) with a slight excess of 2-amino-1,3-propanediol (commonly named serinol) also dissolved in dimethylacetamide, in the presence of tributylamine to give the compound (II), S-N,N′-bis[2-hydroxy-1-(hydroxymethyl)ethyl]-5-[(2-(acetyloxy)-1-oxopropyl)amino]-2,4,6-triiodo-1,3-benzenedicarboxamide.
The ratio between compound (II), serinol and tributylamine, expressed in equivalents, is 1:2.5:2. The reaction is carried out at 50° C. and, after some hours, the desired product is obtained in a 92% yield.
The work up of the reaction mixture, described in the cited Patent, comprises evaporating dimethylacetamide, suspending the oily residue in methylene chloride, taking up repeatedly the precipitate with hot methylene chloride.
The resulting residue is then hydrolysed to Iopamidol with NaOH and the resulting solution is subsequently purified from the salts by treatment with a cationic resin and an anionic one, then recrystallized from ethyl alcohol.
The main problems with this process are the following ones:
the distillation of the solvent under vacuum at the end of the reaction is a very troublesome operation from the industrial point of view, DMAC being a high boiling product (165° C.);
the use of DMAC gives rise to the presence of N-[2-hydroxy-1-(hydroxymethyl)ethyl]-N′-dimethyl-5-[(2-hydroxy-oxopropyl)amino]-2,4,6-triiodo-1,3-benzenedicarboxamide
10 i.e. one of the seven impurities of Iopamidol described in Pharmeuropa, vol. 6, n°4, Dececember 1994, p. 343-345, which is essentially ascribable to the production of dimethylamine by DMAC during the work up of the reaction;
furthermore, the use of such a high boiling solvent is troublesome and difficult as traces thereof remain in the recovered solid product, which traces must not, however, exceed 650 ppm (USP limit for Iopamidol).
A first attempt to replace DMAC consists in GB Patent 2,272,218 (priority Oct. 27, 1992), which only discloses the preparation of compound (II) by using solvents different from DMAC, i.e. acetone or lower alcohols (C
1
-C
4
), in the presence of a base, preferably tributylamine.
As recognized by the inventors themselves in GB patent application 2.311.524, which has been published subsequently and will be discussed in the following, Iopamidol obtained from intermediate (II), albeit having an acceptable purity level, also contained different impurities instead of impurity I.
The medical profession and the rules concerning the marketing authorizations of medicaments, require medicaments with extremely low impurities contents so as to minimize the related risks of side-effects or toxic effects for the patient.
In the case of the iodinated contrast agents such need is particularly justified as the total amount of product administered is many orders of magnitude higher than other medicaments. Only by way of example, the dose or opacifying agent injected can reach and even exceed 150 g.
In fact, the pharmacopoeia standards of Iopamidol have recently been modified, (Italian Pharmacopoeia IX, 3rd revision, 1994; US Pharmacopoeia XXIII, 5th revision, Nov. 15, 1996) in that Iopamidol should contain a maximum of 0.25% impurities.
Recently published GB patent application 2,311,524 (priority Mar. 29, 1996), discloses an alternative method for the preparation of Iopamidol with such purity characteristics.
GB 2,311,524 discloses the preparation of compound (I), using N-methylpyrrolidone as reaction solvent, in the presence of a base, preferably selected from serinol, tributylamine, triethylamine or an inorganic carbonate, and it claims a higher purity of the resulting compound (II) which favourably affects the final purity of Iopamidol.
The preferred process described comprises the reaction of compound (III) with serinol in N-methylpyrrolidone and in the presence of previously purified triethylamine or sodium carbonate. The subsequent treatment of the resulting crude through a battery of ion exchange resins (strongly cationic, weakly anionic, strongly anionic, weak anionic, as described in GB 2.287.024) gives the final compound Iopamidol, with a purity which apparently meets the pharmacopoeia standards.
It is therefore evident from the prior art the increasing need to avoid the use of DMAC, which would also be advantageous in terms of impurities present in Iopamidol while improving the carrying out of the industrial process.
Moreover, N-methylpyrrolidone belongs to the same class of dipolar aprotic solvents as DMAC and it has the same boiling point characteristics, and it is therefore difficult to be removed completely.
It has now surprisingly been found that Iopamidol can be prepared in accordance with the pharmacopoeia standards by the process of the invention comprising:
a novel method for the preparation of compound (II);
the easy transformation of the resulting compound (II) into Iopamidol, involving neither basic hydrolysis nor complex chromatographic treatments.
It is therefore the object of the present invention a process for the preparation of compound (I) comprising the formation of compound (II) by reaction of compound (III) in the presence of only serinol, without solvent, followed by hydrolysis of the acetate group.
It has surprisingly been found that the reaction can be carried out without solvent and without addition of a base, in particular tributylamine as in the prior art, thereby effectively solving the problems mentioned above connected with the presence of DMAC, while obtaining a final product with the purity characteristics in accordance with the pharmacopoeia standards.
As already described in international patent application WO 92/14539, it was already known from the prior art that the reaction can be carried out without a base, using more than 4 equivalents of serinol, which acts as binding agent of the hydrochloric acid formed during the reaction. The reaction was however carried out still in DMAC thus involving the above mentioned problems.
It has surprisingly been found that adding serinol in a molar ratio to compound (III) ranging from 6 to 25, preferably from 8 to 16, the use of a solvent to carry out the condensation reaction between compound (III) and serinol is no more necessary.
Moreover, the serinol excess allows to avoid the addition of a base for the subsequent hydrolysis of compound (II) to Iopamidol.
The temperature of the condensation reaction can range from 30° C. to 70° C., preferably from 38 to 55° C.
The time of the condensation reaction can range from 24 to 100 h, preferably from 40 to 72 h.
At the end of the reaction between serinol and compound (III), monitored by HPLC analysis, the acetate group is hydrolysed by addition of water, preferably in amounts of 2 to 4 kg of water per mol of compound (III): the solution is already basic due to the presence of the serinol excess.
The temperature of the solution is suitably adjusted to 50-70° C., preferably 55-65° C., and kept for a time ranging from 1 to 8 h, preferably from 2 to 5 h. At the end the mixture is neutralized by addition of HCl.
Operating according to the process of the invention, the final reac

Affiliated with

Also associated with

Rating

Process for the preparation of S-N,N′-bis... does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Process for the preparation of S-N,N′-bis..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Process for the preparation of S-N,N′-bis... will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2985436